Payment overview · 2025
General Payments
$2,579.58
107 reported records · 36 companies
Healthcare provider profile · identity verified
Shahnaz Ali, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRAND RAPIDS, MI · NPI 1922020478
Verified facts
What the public records show
CMS Open Payments records show Shahnaz Ali, M.D. received $2,579.58 in general payments during 2025 across 107 reported records.
PFIZER INC. accounted for 9.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $242.94 | 9.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $205.89 | 8.0% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $179.62 | 7.0% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $176.20 | 6.8% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $170.20 | 6.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $163.58 | 6.3% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $140.61 | 5.5% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $132.40 | 5.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.13 | 3.4% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $85.28 | 3.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.70 | 3.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $81.43 | 3.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.62 | 3.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.98 | 3.0% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.77 | 2.9% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $73.50 | 2.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.71 | 2.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.16 | 2.1% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $51.06 | 2.0% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$38.56 | 1.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.66 | 1.2% | 2 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $26.01 | 1.0% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $24.49 | 0.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.85 | 0.9% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $22.17 | 0.9% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $21.97 | 0.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.87 | 0.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.76 | 0.8% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $20.58 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.82 | 0.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.73 | 0.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.32 | 0.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $17.12 | 0.7% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $15.06 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.27 | 0.6% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.56 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,579.58 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $281.09 | 9 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $176.20 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $171.72 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $170.20 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $160.46 | 11 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $140.61 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $132.40 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $85.28 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.70 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $81.43 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.62 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $73.50 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $72.41 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.71 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $54.59 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $51.06 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.63 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.63 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.97 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.66 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $31.47 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $29.80 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.10 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.10 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $9.44 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $3.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 145 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
116 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 425 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 59 |
| Lisinopril | Lisinopril | 169 | 62 |
| Gabapentin | Gabapentin | 161 | 46 |
| Omeprazole | Omeprazole | 160 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 33 |
| Eliquis | Apixaban | 145 | 31 |
| Alprazolam | Alprazolam | 137 | 39 |
| Losartan Potassium | Losartan Potassium | 128 | 43 |
| Liothyronine Sodium | Liothyronine Sodium | 125 | 42 |
| Progesterone | Progesterone, Micronized | 121 | 44 |
| Armour Thyroid | Thyroid,pork | 116 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 36 |
| Trazodone Hcl | Trazodone Hcl | 105 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 37 |
| Lorazepam | Lorazepam | 82 | 26 |
| Bupropion Xl | Bupropion Hcl | 79 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 19 |
| Furosemide | Furosemide | 75 | 25 |
| Potassium Chloride | Potassium Chloride | 64 | 20 |
| Buspirone Hcl | Buspirone Hcl | 61 | 20 |
| Tramadol Hcl | Tramadol Hcl | 60 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 16 |
| Carvedilol | Carvedilol | 57 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 22 |
| Estradiol (Twice Weekly) | Estradiol | 55 | 21 |
| Montelukast Sodium | Montelukast Sodium | 55 | 14 |
| Synthroid | Levothyroxine Sodium | 52 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 13 |
| Meloxicam | Meloxicam | 50 | 19 |
| Sertraline Hcl | Sertraline Hcl | 49 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 11 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Metformin Hcl | Metformin Hcl | 41 | 20 |
| Metformin Hcl Er | Metformin Hcl | 41 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Atenolol | Atenolol | 37 | 12 |
| Dotti | Estradiol | 37 | 15 |
| Simvastatin | Simvastatin | 37 | 12 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 20 |
| Allopurinol | Allopurinol | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 12 |
| Ozempic | Semaglutide | 33 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | 11 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 14 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 14 |
| Baclofen | Baclofen | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Estradiol | Estradiol | 28 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 21 |
| Naltrexone Hcl | Naltrexone Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nystatin | Nystatin | 26 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 13 |
| Risperidone | Risperidone | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Prednisone | Prednisone | 20 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Folic Acid | Folic Acid | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Klayesta | Nystatin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,579.58 · 107 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Arikayce, Auvelity, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dojolvi, ELIQUIS, FARXIGA, Flector, GEMTESA, IBSRELA, INGREZZA, INJECTAFER, INSPIRE, JARDIANCE, JATENZO, Kerendia, LEQVIO, LINZESS, Leqembi, Licart, MYFEMBREE, NURTEC ODT, Nayzilam, ONPATTRO, PREVNAR 20, QULIPTA, REXULTI, SHINGRIX, SPRAVATO, Senza, TONMYA, TRELEGY ELLIPTA, Tirosint, UBRELVY, VALTOCO, VRAYLAR, VYNDAMAX, VYNDAQEL, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error